To stop or not to stop: The quest for long‐term viral suppression

Hepatitis B surface antigen levels after hepatitis B e‐antigen seroclearance: a longitudinal follow‐up study

“…Importantly, a significant proportion of patients who undergo HBeAg seroclearance will continue to demonstrate disease activity leading to progression to cirrhosis and HCC . Similarly, for those who undergo HBeAg seroclearance while on antiviral therapy, a significant proportion will have evidence of virological rebound if the antiviral therapy is discontinued .…”